The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder.
R. Joober sits on the advisory boards and speakers’ bureaus of Pfizer, Janssen Ortho, BMS, Sunovion, Otsuka, Lundbeck, Perdue and Myelin; he has received grant funding from them and from AstraZeneca and HLS. He has received honoraria from Janssen Canada, Shire, Lundbeck, Otsuka, Pfizer and Perdue for CME presentations and royalties from Henry Stewart talks. He is co-editor in chief of JPN, and was not involved in the review of this manuscript or in the decision to accept it for publication. No other competing interests were declared.